Liraglutide Leads to Increased Weight Loss Response in Patients Without Diabetes

Summary

Indicated for use in patients who were overweight (body mass index ≥ 27 kg/m2 with ≥ 1 comorbidities) or obese (body mass index ≥ 30 kg/m2) without diabetes mellitus, liraglutide has proven safe and effective in the SCALE–Obesity and Prediabetes trial. Combined with diet and exercise, liraglutide can improve weight and health-related quality-of-life factors.

  • liraglutide
  • weight loss
  • weight management
  • SCALE trial
  • GLP-1
  • waist circumference
  • fasting plasma glucose
View Full Text